Living well with multiple sclerosis

American Journal of Nursing

Volumn 111, Issue 7, 2011, Pages 40-48

  Brodkey, Marion Brandis ^a   Ben Zacharia, Aliza Bitton ^b   Reardon, Jennifer Decker ^c  

^a Cabrillo College   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c Northern Westchester Hospital   (United States)

Author keywords

autoimmune diseases; multiple sclerosis; nervous system diseases; neurodegenerative diseases; neurologic diseases; relapsing remitting multiple sclerosis

Indexed keywords

ADULT; ARTICLE; CONTINUING EDUCATION; HUMAN; MULTIPLE SCLEROSIS; NURSE ATTITUDE; NURSING; PATHOPHYSIOLOGY;

ADULT; EDUCATION, CONTINUING; HUMANS; MULTIPLE SCLEROSIS; NURSE'S ROLE;

EID: 79959950754     PISSN: 0002936X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.NAJ.0000399314.36526.f4     Document Type: Article

References (43)

1. Ben-Zacharia AB, Del Bene ML. Inflammatory demyelinating diseases: multiple sclerosis. In: Barker EM, editor. Neuroscience nursing: a spectrum of care. 3rd ed. St. Louis: Elsevier Mosby; 2008. p. 602-3.
2. National Multiple Sclerosis Society. Epidemiology of MS. n.d. http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/ who-gets-ms/epidemiology-of-ms/index.aspx.
3. Burt RK, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009;8(3):244-53.
4. Whetten-Goldstein K, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4(5):419-25. (Pubitemid 28515352)
5. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46(4):907-11. (Pubitemid 26134623)
6. Rovaris M, et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006;5(4):343-54.
7. Miller DH, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14(9):1157-74.
8. Calabresi PA. Diagnosis and management of multiple sclerosis. Am Fam Physician 2004;70(10):1935-44. (Pubitemid 39532194)
9. McDonald WI, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50(1):121-7.
10. Holland NJ, Madonna M. Nursing grand rounds: multiple sclerosis. J Neurosci Nurs 2005;37(1):15-9.
11. Yadav V, et al. Use and self-reported benefit of complementary and alternative medicine among multiple sclerosis patients. International Journal of MS Care 2006;8(1):5-10.
12. Halper J, Holland NJ, editors. Comprehensive nursing care in multiple sclerosis. 2nd ed. New York: Demos; 2002.
13. National Multiple Sclerosis Society. Recommendations regarding corticosteroids in the management of multiple sclerosis. New York; 2008. Expert opinion paper; http://www.nationalmssociety.org/download.aspx?id=553.
14. Cortese I, et al. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;76(3):294-300.
15. National Multiple Sclerosis Society. Optic neuritis. n.d. http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/ symptoms/visualsymptoms/optic-neuritis/index.aspx.
16. Goodin DS, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58(2):169-78. (Pubitemid 34086933)
17. Paolicelli D, et al. Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics 2009;3:369-76.
18. Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology 2004;63(12 Suppl 6):S8-S14. (Pubitemid 40019272)
19. IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45(7):1277-85.
20. Jacobs L, Johnson KP. A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol 1994;51(12):1245-52.
21. Durelli L, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359(9316):1453-60. (Pubitemid 34457761)
22. Kappos L, et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 2001;57(11):1969-75. (Pubitemid 33126860)
23. Goodin DS, et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61(10):1332-8. (Pubitemid 37463366)
24. Marriott JJ, et al. Evidence report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;74(18):1463-70.
25. Cocco E, et al. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler 2008;14(9):1225-33.
26. Polman CH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(9):899-910.
27. Miller DH, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007;68(17):1390-401. (Pubitemid 46659091)
28. U.S. Food and Drug Administration. FDA drug safety communication: safety update on progressive multifocal leukoencephalopathy (PML) associated with Tysabri (natalizumab). Silver Spring, MD; 2011.
29. Yeh EA, Weinstock-Guttman B. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis. Adv Ther 2011;28(4):270-8.
30. Cohen JA, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362(5):402-15.
31. National Multiple Sclerosis Society. Pregnancy and reproductive rights. n.d. http://www.nationalmssociety.org/living-with-multiple-sclerosis/healthy- living/pregnancy/index.aspx.
32. Morgante L, et al. Decision making in multiple sclerosis: theory to practice. International Journal of MS Care 2006;8(4):113-20.
33. Minden S, et al. Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study. Mult Scler 2008;14(5):640-55. (Pubitemid 351954407)
34. von Schaper E, Kresge N. Novartis's $48,000 pill spurs U.S. price increases for older MS treatments. Bloomberg 2011 Mar 21. http://www.bloomberg. com/news/2011-03-21/novartis-s-48-000-pill-spurs-u-s-price-increases-for-ms- drugs.html.
35. Kolata G. Co-payments soar for drugs with high prices. New York Times 2008 Apr 14. https://www.nytimes.com/2008/04/14/us/14drug.html.
36. Holland N. Improving adherence to therapy with immunomodulating agents. New York: National Multiple Sclerosis Society; 2002. Clinical bulletin; http://www.nationalmssociety.org/download.aspx?id=160.
37. Bodenheimer T, et al. Patient self-management of chronic disease in primary care. JAMA 2002;288(19):2469-75. (Pubitemid 35340544)
38. Denny LL, Thurston D. New multiple sclerosis therapies and the new paradigm of adherence. International Journal of MS Care 2008;10(Suppl 2):24-8.
39. Holland N, et al. Adherence to disease-modifying therapy in multiple sclerosis: Part I. Rehabil Nurs 2001;26(5):172-6.
40. Fraser C, et al. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2001;33(5):231-9.
41. Fraser C, et al. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs 2004;36(3):120-9.
42. Bandura A. Self-efficacy: the exercise of control. New York: W.H. Freeman and Company; 1997.
43. Saunders C, et al. Factors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosis. J Neurosci Nurs 2010;42(5 Suppl):S10-S18.